RxDoctor Payments Data

Jeanne Knight, NP

Psychiatric/Mental Health · Newport, RINPI 1174588875

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 27.8% of the total. 2025 is the largest year on record at $1,948, 5.2 times the $375 reported in 2021. Among psychiatric/mental health clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,279in general payments, 2019–2025

Across 167 payments — averaging $37.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Vanda Pharmaceuticals Inc.$1K
  • Neurocrine Biosciences, Inc.$724
  • Axsome Therapeutics, Inc.$472
  • Johnson & Johnson$355
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$348
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$6,16798%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,279 in reported general payments places this provider in the 90th percentile of 196 psychiatric/mental health providers in Rhode Island.

See all psychiatric/mental health providers in Rhode Island

Medicare billing

Part B allowed, 2024
$36,737
Medicare patients
125
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Desvenlafaxine Succinate ErDesvenlafaxine Succinate92$6,615
Quetiapine Fumarate48$790
Duloxetine Hcl18$574
Clonazepam71$497
Mirtazapine20$492
Bupropion XlBupropion Hcl19$337
Trazodone Hcl57$330
Bupropion Hcl16$288
Escitalopram Oxalate30$287
Venlafaxine Hcl ErVenlafaxine Hcl13$184
Amlodipine Besylate11$84
Diazepam21$80
Lorazepam26$64
Azithromycin14$34

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Newport

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →